ReviewMedical molecular morphology2013
Clinical significance of cell cycle inhibitors in hepatocellular carcinoma.
Review in Medical molecular morphology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Article
- Article
- MHIF-MSEA: a novel model of miRNA set enrichment analysis based on multi-source heterogeneous information fusion.Frontiers in genetics · 2024Article
- Article
- Construction of a prognostic risk model based on apoptosis-related genes to assess tumor immune microenvironment and predict prognosis in hepatocellular carcinoma.BMC gastroenterology · 2022Article
- Clinical Significance and Prognostic Value of Lactate Dehydrogenase Expression in Cervical Cancer.Genetic testing and molecular biomarkers · 2022Article
- Article
- Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma.Cancers · 2019Article
- Systems biology based meth-miRNA-mRNA regulatory network identifies metabolic imbalance and hyperactive cell cycle signaling involved in hepatocellular carcinoma onset and progression.Cancer cell international · 2019Article
- [Expression of cyclin Y in hepatocellular carcinoma cells and its correlation with clinical characteristics of hepatocellular carcinoma patients].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018Article
- The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.Molecular cancer · 2018Article
- Cyclin Y Modulates the Proliferation, Invasion, and Metastasis of Hepatocellular Carcinoma Cells.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Upregulation of BUB1B, CCNB1, CDC7, CDC20, and MCM3 in Tumor Tissues Predicted Worse Overall Survival and Disease-Free Survival in Hepatocellular Carcinoma Patients.BioMed research international · 2018Article
- A novel matrine derivate inhibits differentiated human hepatoma cells and hepatic cancer stem-like cells by suppressing PI3K/AKT signaling pathways.Acta pharmacologica Sinica · 2017Article
- Tumorigenic potential is restored during differentiation in fusion-reprogrammed cancer cells.Cell death & disease · 2016Article
- Liver specific expression of Cu/ZnSOD extends the lifespan of Sod1 null mice.Mechanisms of ageing and development · 2016Article
- Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.World journal of hepatology · 2015Review
- Upregulation of cyclin-dependent kinase inhibitors CDKN1B and CDKN1C in hepatocellular carcinoma-derived cells via goniothalamin-mediated protein stabilization and epigenetic modifications.Toxicology reports · 2015Article
- Genetic polymorphisms in apoptosis-related genes and the prognosis of hepatocellular carcinoma.American journal of cancer research · 2015Article
- The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations.Cancers · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well accepted that cell cycle regulators are strongly implicated in the progression of cancer development. p16 and p27 are potent cyclin-dependent kinase (CDK) inhibitors involved in G1 phase progression, and are regarded as adverse prognostic biomarkers for various types of cancers. It has been reported that the main mechanism for p16 inactivation is aberrant DNA methylation, while p27 is exclusively inactivated by proteasome-mediated protein degradation. We have found that p27 is decreased in around half of hepatocellular carcinomas (HCCs), and in some cases p27 is inactivated by inappropriate interaction with cyclin D1/CDK4 complexes. In such cases, p16 is concomitantly inactivated through DNA methylation. Taking into consideration the complex interaction between p16 and p27, a comprehensive analysis including p16 and p27 would be useful for predicting the prognosis of HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.